Aastrom's heart failure drug enters midstage development

04/8/2013 | Pharmaceutical Business Review Online

Aastrom Biosciences has started recruiting patients for a Phase IIb trial that will assess the safety and efficacy of its experimental drug Ixmyelocel-T in people with advanced heart failure due to ischemic dilated cardiomyopathy. The randomized, double-blind trial will involve 108 patients.

View Full Article in:

Pharmaceutical Business Review Online

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC